Abstract
Small heterodimer partner (SHP, NR0B2) is a nuclear receptor that exerts influence over the expression of several nuclear receptors and transcription factors. We have previously shown that SHP is involved in several metabolic and cellular processes. Of particular interest, SHP appears to play a crucial role as a tumor suppressor. We have recently published work demonstrating that SHP knockout (SHP-/-) mice spontaneously develop hepatocellular carcinoma. We have discovered that SHP is a potent inhibitor of cellular proliferation, and that activation of SHP induces apoptosis and inhibits tumor growth. In collateral studies, we have also found that SHP is a key regulator of microRNA gene transcription and through this process can activate apoptosis. Furthermore, we have also shown that SHP expression can be influenced by the degree of methylation. The ability to modulate key cellular processes, particularly cellular proliferation and apoptosis, has heightened interest in the ability of this protein to function as a therapeutic target in hepatomas, as well as other neoplasms. Future research will also examine the sensitivity and specificity of SHP to function as a biomarker for hepatocellular carcinoma.
Keywords: Nuclear receptor, gene transcription, cell cycle, apoptosis, liver cancer.
Current Cancer Therapy Reviews
Title:Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Volume: 6 Issue: 4
Author(s): Jenny Hatch, Shiguo Liu, Timothy Gayowski, John Sorensen and Li Wang
Affiliation:
Keywords: Nuclear receptor, gene transcription, cell cycle, apoptosis, liver cancer.
Abstract: Small heterodimer partner (SHP, NR0B2) is a nuclear receptor that exerts influence over the expression of several nuclear receptors and transcription factors. We have previously shown that SHP is involved in several metabolic and cellular processes. Of particular interest, SHP appears to play a crucial role as a tumor suppressor. We have recently published work demonstrating that SHP knockout (SHP-/-) mice spontaneously develop hepatocellular carcinoma. We have discovered that SHP is a potent inhibitor of cellular proliferation, and that activation of SHP induces apoptosis and inhibits tumor growth. In collateral studies, we have also found that SHP is a key regulator of microRNA gene transcription and through this process can activate apoptosis. Furthermore, we have also shown that SHP expression can be influenced by the degree of methylation. The ability to modulate key cellular processes, particularly cellular proliferation and apoptosis, has heightened interest in the ability of this protein to function as a therapeutic target in hepatomas, as well as other neoplasms. Future research will also examine the sensitivity and specificity of SHP to function as a biomarker for hepatocellular carcinoma.
Export Options
About this article
Cite this article as:
Hatch Jenny, Liu Shiguo, Gayowski Timothy, Sorensen John and Wang Li, Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer, Current Cancer Therapy Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339410793358084
DOI https://dx.doi.org/10.2174/157339410793358084 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Current Drug Discovery Technologies Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry L1 Retrotransposon and Retinoblastoma: Molecular Linkages Between Epigenetics and Cancer
Current Molecular Medicine Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer
Current Gene Therapy Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism Synthetic and Biological Aspects of Thiadiazoles and their Condensed Derivatives: An Overview
Current Topics in Medicinal Chemistry Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Synthesis and Evaluation of Cytotoxic Activity of Some Pyrroles and Fused Pyrroles
Anti-Cancer Agents in Medicinal Chemistry Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Chlorella vulgaris: A Multifunctional Dietary Supplement with Diverse Medicinal Properties
Current Pharmaceutical Design